<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Am J Hum Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Am J Hum Genet</journal-id>
      <journal-title-group>
        <journal-title>American Journal of Human Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0002-9297</issn>
      <issn pub-type="epub">1537-6605</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33979636</article-id>
      <article-id pub-id-type="pmc">8206387</article-id>
      <article-id pub-id-type="pii">S0002-9297(21)00148-8</article-id>
      <article-id pub-id-type="doi">10.1016/j.ajhg.2021.04.017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Impaired glucose-1,6-biphosphate production due to bi-allelic <italic>PGM2L1</italic> mutations is associated with a neurodevelopmental disorder</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au1">
          <name>
            <surname>Morava</surname>
            <given-names>Eva</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au2">
          <name>
            <surname>Schatz</surname>
            <given-names>Ulrich A.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
          <xref rid="aff3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author" id="au3">
          <name>
            <surname>Torring</surname>
            <given-names>Pernille M.</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author" id="au4">
          <name>
            <surname>Abbott</surname>
            <given-names>Mary-Alice</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author" id="au5">
          <name>
            <surname>Baumann</surname>
            <given-names>Matthias</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author" id="au6">
          <name>
            <surname>Brasch-Andersen</surname>
            <given-names>Charlotte</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">4</xref>
          <xref rid="aff7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author" id="au7">
          <name>
            <surname>Chevalier</surname>
            <given-names>Nathalie</given-names>
          </name>
          <xref rid="aff8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author" id="au8">
          <name>
            <surname>Dunkhase-Heinl</surname>
            <given-names>Ulrike</given-names>
          </name>
          <xref rid="aff9" ref-type="aff">9</xref>
        </contrib>
        <contrib contrib-type="author" id="au9">
          <name>
            <surname>Fleger</surname>
            <given-names>Martin</given-names>
          </name>
          <xref rid="aff10" ref-type="aff">10</xref>
        </contrib>
        <contrib contrib-type="author" id="au10">
          <name>
            <surname>Haack</surname>
            <given-names>Tobias B.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
          <xref rid="aff11" ref-type="aff">11</xref>
          <xref rid="aff12" ref-type="aff">12</xref>
        </contrib>
        <contrib contrib-type="author" id="au11">
          <name>
            <surname>Nelson</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref rid="aff13" ref-type="aff">13</xref>
        </contrib>
        <contrib contrib-type="author" id="au12">
          <name>
            <surname>Potelle</surname>
            <given-names>Sven</given-names>
          </name>
          <xref rid="aff8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author" id="au13">
          <name>
            <surname>Radenkovic</surname>
            <given-names>Silvia</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="aff14" ref-type="aff">14</xref>
        </contrib>
        <contrib contrib-type="author" id="au14">
          <name>
            <surname>Bommer</surname>
            <given-names>Guido T.</given-names>
          </name>
          <xref rid="aff8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author" id="au15">
          <name>
            <surname>Van Schaftingen</surname>
            <given-names>Emile</given-names>
          </name>
          <xref rid="aff8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author" id="au16">
          <name>
            <surname>Veiga-da-Cunha</surname>
            <given-names>Maria</given-names>
          </name>
          <email>maria.veiga@uclouvain.be</email>
          <xref rid="aff8" ref-type="aff">8</xref>
          <xref rid="cor1" ref-type="corresp">&#x2217;</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Clinical Genomics, Mayo Clinic, Rochester, MN 55905, USA</aff>
        <aff id="aff2"><label>2</label>Institute of Human Genetics, Department of Genetics and Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria</aff>
        <aff id="aff3"><label>3</label>Institute of Human Genetics, Technische Universit&#xE4;t M&#xFC;nchen, 81675 Munich, Germany</aff>
        <aff id="aff4"><label>4</label>Department of Clinical Genetics, Odense University Hospital, 5000 Odense, Denmark</aff>
        <aff id="aff5"><label>5</label>Medical Genetics, Department of Pediatrics, University of Massachusetts Medical School &#x2013; Baystate, Springfield, MA 01199, USA</aff>
        <aff id="aff6"><label>6</label>Department of Pediatrics I, Division of Pediatric Neurology, Medical University Innsbruck, 6020 Innsbruck, Austria</aff>
        <aff id="aff7"><label>7</label>Human Genetics, Faculty of Health, University of Southern Denmark, 5000 Odense, Denmark</aff>
        <aff id="aff8"><label>8</label>de Duve Institute, UCLouvain, 1200 Brussels, Belgium</aff>
        <aff id="aff9"><label>9</label>Department of Pediatrics, Hospital of Southern Jutland, 6200 Aabenraa, Denmark</aff>
        <aff id="aff10"><label>10</label>Department of Pediatrics, Landeskrankenhaus Bregenz, 6900 Bregenz, Austria</aff>
        <aff id="aff11"><label>11</label>Institute of Medical Genetics and Applied Genomics, University of T&#xFC;bingen, 72076 T&#xFC;bingen, Germany</aff>
        <aff id="aff12"><label>12</label>Centre for Rare Diseases, University of T&#xFC;bingen, 72076 T&#xFC;bingen, Germany</aff>
        <aff id="aff13"><label>13</label>Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA</aff>
        <aff id="aff14"><label>14</label>Metabolomics Expertise Center, VIB-KU Leuven, 3000 Leuven, Belgium</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>&#x2217;</label>Corresponding author <email>maria.veiga@uclouvain.be</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>5</month>
        <year>2021</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <day>03</day>
        <month>6</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>5</month>
        <year>2021</year>
      </pub-date>
      <volume>108</volume>
      <issue>6</issue>
      <fpage>1151</fpage>
      <lpage>1160</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>1</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>4</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2021 The Author(s)</copyright-statement>
        <copyright-year>2021</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
          <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <title>Summary</title>
        <p>We describe a genetic syndrome due to PGM2L1 deficiency. PGM2 and PGM2L1 make hexose-bisphosphates, like glucose-1,6-bisphosphate, which are indispensable cofactors for sugar phosphomutases. These enzymes form the hexose-1-phosphates crucial for NDP-sugars synthesis and ensuing glycosylation reactions. While PGM2 has a wide tissue distribution, PGM2L1 is highly expressed in the brain, accounting for the elevated concentrations of glucose-1,6-bisphosphate found there. Four individuals (three females and one male aged between 2 and 7.5 years) with bi-allelic inactivating mutations of <italic>PGM2L1</italic> were identified by exome sequencing. All four had severe developmental and speech delay, dysmorphic facial features, ear anomalies, high arched palate, strabismus, hypotonia, and keratosis pilaris. Early obesity and seizures were present in three individuals. Analysis of the children&#x2019;s fibroblasts showed that glucose-1,6-bisphosphate and other sugar bisphosphates were markedly reduced but still present at concentrations able to stimulate phosphomutases maximally. Hence, the concentrations of NDP-sugars and glycosylation of the heavily glycosylated protein LAMP2 were normal. Consistent with this, serum transferrin was normally glycosylated in affected individuals. PGM2L1 deficiency does not appear to be a glycosylation defect, but the clinical features observed in this neurodevelopmental disorder point toward an important but still unknown role of glucose-1,6-bisphosphate or other sugar bisphosphates in brain metabolism.</p>
      </abstract>
      <kwd-group id="kwrds0010">
        <title>Keywords</title>
        <kwd>IMP</kwd>
        <kwd>brain development</kwd>
        <kwd>PMM1</kwd>
        <kwd>glucose-1,6-bisphosphate synthase</kwd>
        <kwd>glucose-1,6-bisphosphatase</kwd>
        <kwd>phosphoglucomutase</kwd>
        <kwd>congenital disorders of glycosylation</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <p id="misc0010">Published: May 11, 2021</p>
    </notes>
  </front>
  <body>
    <sec id="sec1">
      <title>Main text</title>
      <p id="p0010">Glycosylation defects are a major group of metabolic diseases comprising more than 100 different defects and a&#xA0;significant proportion of them are due to deficiencies in enzymes involved in the synthesis of nucleoside diphosphate sugars (NDP-sugars).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> In several instances, the synthesis of NDP-sugars starts with the conversion of a hexose-6-phosphate to a hexose-1-phosphate. This step is catalyzed by a phosphomutase and is followed by the addition of a nucleotidyl group to the phosphate on carbon 1, resulting in the activated sugars uridine diphosphate (UDP)-glucose, UDP-<italic>N</italic>-acetyl-glucosamine, and guanosine diphosphate (GDP)-mannose. The three phosphomutases that are needed to form glucose-1-phosphate (phosphoglucomutase 1 [PGM1]),<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> N-acetyl-glucosamine-1-phosphate (phosphoglucomutase 3 [PGM3]),<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> and mannose-1-phosphate (phosphomannomutase 2 [PMM2])<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> all require low&#xA0;concentrations of the corresponding hexose-bisphosphate&#xA0;(glucose-, N-acetyl-glucosamine-, and mannose-1,6-bisphosphate) as a cofactor.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> This cofactor participates in the reaction mechanism and is therefore indispensable.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p>
      <p id="p0015">The main enzymatic reaction forming these hexose-bisphosphates uses the high-energy intermediate of glycolysis 1,3-bisphosphoglycerate as a phosphoryl donor and a hexose-1 or 6-phosphate as a phosphate acceptor.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> In vertebrates, two proteins have been shown to catalyze this reaction: PGM2 and PGM2L1. PGM2 is a multifunctional enzyme able to catalyze several phosphomutase reactions on ribose-phosphate, deoxyribose-phosphate, and glucose-phosphate and, at a much lower rate, the synthesis of hexose-1,6-bisphosphates and ribose-1,5-bisphosphate.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> PGM2L1 has similar catalytic activities, but its bisphosphate synthesizing activity is higher compared to its mutase activity, which makes it suitable to synthesize high concentrations of glucose-1,6-bisphosphate and other hexose- and pentose-bisphosphates.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> This is also consistent with the tissue distribution of these two enzymes: PGM2 is widely distributed in tissues, while PGM2L1 is almost restricted to the brain. Intriguingly, the brain is characterized by a very high concentration of glucose-1,6-bisphosphate (&gt;100&#xA0;&#x3BC;M), which is at least 100-fold more than the concentration needed for the functioning of sugar phosphomutases.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> These findings suggest that glucose-1,6-bisphosphate and PGM2L1 play a still unknown role in the brain. Here, we report the identification of four children with PGM2L1 deficiency sharing a common, largely neurological phenotype. More than 10 years after the molecular identification of PGM2L1,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> the discovery of this developmental disorder highlights the importance of glucose-1,6-bisphosphate in the brain.</p>
      <p id="p0020">We performed clinical whole-exome sequencing (WES) in all four families as WES trio analysis (<xref rid="mmc1" ref-type="supplementary-material">supplemental subjects and methods</xref>) to explore the cause of an identified neurodevelopmental disease affecting young children. This disclosed bi-allelic variants in <italic>PGM2L1</italic> in all four affected children (PT1, PT2, PT3, and PT4&#x2014;see <xref rid="tbl1" ref-type="table">Table 1</xref>), which were connected via the web-based tool GeneMatcher.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> The <italic>PGM2L1</italic> (MIM: <ext-link ext-link-type="omim" xlink:href="611610" id="intref0010">611610</ext-link>) variants identified (GenBank: <ext-link ext-link-type="uri" xlink:href="ncbi-n:NM_173582.4" id="intref0015">NM_173582.4</ext-link>) were as follows: for PT1, homozygous variant c.1548_1549delTC (p.Pro517Lys<sup>&#x2217;</sup>19); for PT2, compound heterozygous for the frameshift variants c.51delC (p.Tyr18Thrfs<sup>&#x2217;</sup>36) and c.1115delA (p.Asn372Ilefs<sup>&#x2217;</sup>8); for PT3, homozygous truncating variant c.172C&gt;T (p.Arg58<sup>&#x2217;</sup>); and for PT4, homozygous truncating variant c.1282G&gt;T (p.Glu428<sup>&#x2217;</sup>). In addition, microarray analysis did not identify any clinically relevant copy number variations in any of the affected individuals and none of the additional gene variants identified appeared to contribute to the phenotype (<xref rid="mmc1" ref-type="supplementary-material">supplemental subjects and methods</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Clinical features of four PGM2L1-deficient individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Individuals</bold></th><th><bold>PT1</bold></th><th><bold>PT2</bold></th><th><bold>PT3</bold><xref rid="tblfn1" ref-type="table-fn">a</xref></th><th><bold>PT4</bold></th></tr></thead><tbody><tr><td>Age/sex</td><td>7 years/male</td><td>7.5 years/female</td><td>7 years/female</td><td>30&#xA0;months/female</td></tr><tr><td>Ethnic background</td><td>Turkish</td><td>French-Canadian (Cajun)</td><td>Middle Eastern</td><td>Pakistani</td></tr><tr><td>Genetic variants (GenBank: <ext-link ext-link-type="uri" xlink:href="ncbi-n:NM_173582.4" id="intref0035">NM_173582.4</ext-link>)</td><td>c.1548_1549delTC (homozygous)</td><td>c.[51delC]; [1115delA]</td><td>c.172C&gt;T (homozygous)</td><td>c.1282G&gt;T (homozygous)</td></tr><tr><td>Protein</td><td>p. Pro517Lysfs<sup>&#x2217;</sup>19</td><td>p.[Tyr18Thrfs<sup>&#x2217;</sup>36]; [Asn372Ilefs<sup>&#x2217;</sup>8]</td><td>p.Arg58<sup>&#x2217;</sup></td><td>p.Glu428<sup>&#x2217;</sup></td></tr><tr><td>Global development delay</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Intellectual disability</td><td>+</td><td>+</td><td>+</td><td>not applicable</td></tr><tr><td>Gross motor skills</td><td>18&#xA0;months sitting, 34&#xA0;months walking</td><td>10&#xA0;months sitting, 18&#xA0;months walking</td><td>7 years can sit/stand with support; no targeted hand activity</td><td>8&#xA0;months sitting, 30&#xA0;months walking</td></tr><tr><td>Speech delay</td><td>single words (4&#x2013;5) at 34&#xA0;months</td><td>severe speech delay</td><td>severe, no verbal language</td><td>30&#xA0;months babbling, no speech</td></tr><tr><td>Abnormal behavior</td><td>no meaningful contact<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td>severe pica and aggressive behavior</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>Neurologic features</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Hypotonia</td><td>+</td><td>+ (truncal)</td><td>shifting tonus, with hypertonia</td><td>+</td></tr><tr><td>Muscle weakness</td><td>+</td><td>+</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>Seizures</td><td>+</td><td>+</td><td>&#x2212;</td><td>+</td></tr><tr><td>Pyramidal signs</td><td>+<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td>&#x2212;</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>Ataxia</td><td>&#x2212;</td><td>+</td><td>&#x2212;</td><td>+</td></tr><tr><td>MRI</td><td>dilation of the frontal interhemispheric cleft</td><td>unremarkable (MRS showed decreased NAA and mildly elevated lactic acid)</td><td>symmetric infra/supra tentorial parenchymal anomalies; signal changes<xref rid="tblfn3" ref-type="table-fn">c</xref></td><td>unremarkable</td></tr><tr><td>Dysmorphic features</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Ears</td><td>over-folded helices, large earlobes, pronounced antitragus</td><td>prominent ears, large ear lobes, and over-folded helices</td><td>large earlobes</td><td>prominent ears</td></tr><tr><td>Eyes</td><td>long eyelashes, down-slanting palpebral fissures</td><td>epicanthal folds, down-slanting palpebral fissures</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>High arched and narrow palate</td><td>+</td><td>+</td><td>+</td><td>&#x2212;</td></tr><tr><td>Nose</td><td>flat nasal bridge, broad and bulbous nasal tip, a long philtrum</td><td>prominent nasal tip, flat nasal bridge, under-developed nasolabial fold</td><td>prominent nose, flat philtrum</td><td>&#x2212;</td></tr><tr><td>Thin upper lip</td><td>+</td><td>+</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>Pointy chin</td><td>+</td><td>&#x2212;</td><td>+</td><td>&#x2212;</td></tr><tr><td>Teeth</td><td>early caries</td><td>early caries</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>Skin abnormalities</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Dry skin</td><td>+ (keratosis pilaris)</td><td>+ (keratosis pilaris)</td><td>+ (keratosis pilaris)</td><td>+ (eczema)</td></tr><tr><td>Abnormal hair growth</td><td>hypertrichosis of the back</td><td>excessive arm hair growth</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>Ocular abnormalities</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Exotropia</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Hypermetropia</td><td>&#x2212;</td><td>&#x2212;</td><td>+</td><td>&#x2212;</td></tr><tr><td>Vision loss</td><td>+<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td>&#x2212;</td><td>&#x2212;</td><td>&#x2212;</td></tr><tr><td>GI abnormalities</td><td>+</td><td>&#x2212;</td><td>&#x2212;</td><td>+</td></tr><tr><td>Swallowing difficulties</td><td>+<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td>&#x2212;</td><td>&#x2212;</td><td>some feeding difficulties</td></tr><tr><td>Early obesity (at age 2 to 3)</td><td>+</td><td>+</td><td>&#x2212;</td><td>+</td></tr><tr><td>Current obesity; BMI/centiles</td><td>+; 19.3/99<sup>th</sup></td><td>+; 25.1/99<sup>th</sup></td><td>&#x2212;; 17.4/85<sup>th</sup></td><td>+; 22.2/99<sup>th</sup></td></tr><tr><td>Extremities</td><td>&#x2212;</td><td>+</td><td>&#x2212;</td><td>+</td></tr><tr><td>Joints</td><td>&#x2212;</td><td>hypermobility</td><td>&#x2212;</td><td>hypermobility</td></tr><tr><td>Hands and feet</td><td>&#x2212;</td><td>small hands and feet and short toes</td><td>&#x2212;</td><td>deep palmar creases</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td colspan="5"><bold>Laboratory investigations</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td>Transferrin glycosylation in blood</td><td>normal</td><td>normal</td><td>normal</td><td>not performed</td></tr><tr><td>Plasma acyl carnitine pattern</td><td>normal</td><td>normal</td><td>normal</td><td>normal</td></tr><tr><td>Urinary organic acids</td><td>normal</td><td>normal</td><td>normal</td><td>normal</td></tr></tbody></table><table-wrap-foot><fn><p>All four pregnancies were unremarkable and birth parameters were normal, except for PT1 in which a relative microcephaly was noted; no cardiac abnormalities and no failure to thrive were detected.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn1"><label>a</label><p id="ntpara0010">Parents are first cousins.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p id="ntpara0015">Symptoms appeared after status epilepticus and resuscitation.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn3"><label>c</label><p id="ntpara0020">Signal changes observed were in lower cerebellar hemispheres, nucleus lentiformis, and scattered on the verge between cortex and white matter.</p></fn></table-wrap-foot></table-wrap></p>
      <p id="p0025">Clinically, all four individuals (three females and one male, between the ages of 2 and 7.5 years) had severe developmental and speech delay, dysmorphic facial features (<xref rid="fig1" ref-type="fig">Figure&#xA0;1</xref>), ear anomalies, high-arched palate, strabismus, muscular hypotonia, and keratitis pilaris/dry skin. All pregnancies were uneventful and growth parameters were normal at birth. There was no significant failure to thrive. Three out of the four children developed significant overweightness after the age of 2 to 3 years (BMI &gt; 97<sup>th</sup> percentile). Two out of the four children had primary ataxia. Three had seizures, including tonic-clonic and absence seizures. One child developed status epilepticus and severely regressed with this event, losing all motor milestones. One child was unable to sit independently or use words. Only one child learned to walk independently and developed speech; this individual had intellectual disability and behavioral abnormalities and demonstrated aggressive outbursts and pica (<xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="mmc1" ref-type="supplementary-material">supplementary subjects and methods</xref>).<fig id="fig1"><label>Figure&#xA0;1</label><caption><p>Dysmorphic features of three PGM2L1-deficient individuals</p><p>(A and B) Individual 1 (PT1) at the age of 1.5 years before status epilepticus occurred (A) and at the age of 5 years after the status epilepticus episode (B); note over-folded helices, large earlobes, pronounced antitragus, down-slanting palpebral fissures, strabismus, flat nasal bridge, broad and bulbous nasal tip, long philtrum, thin upper lip, and small hands.</p><p>(C and D) Individual 2 (PT2) at the age of 7.5 years; note obesity, epicanthal folds, down-slanting palpebral fissures, strabismus, prominent ears and nasal tip, flat nasal bridge, under-developed nasolabial fold, thin upper lip, and pointy chin.</p><p>(E and F) Individual 3 (PT3) at the age of 9 years with strabismus, down-slanting palpebral fissures, broad nasal bridge, bulbous nasal tip, pointy chin, smooth philtrum, and large earlobes.</p></caption><graphic xlink:href="gr1"/></fig></p>
      <p id="p0030">Two children developed early severe caries. None of the children had cardiac, urogenital, endocrine, or skeletal anomalies. Hearing was normal. Vision was impaired only in the affected individual who had a severe episode of status epilepticus. Brain MRI was unremarkable in two affected individuals and a third demonstrated frontal atrophy; in one child, the MRI showed symmetric supratentorial parenchymal anomalies, signal changes in the lower cerebellar hemispheres, in the nucleus lentiformis, and between the cortex and the white matter. One child, who had unremarkable MRI, had a magnetic resonance spectroscopy (MRS) examination, which showed mildly elevated lactic acid and decreased N-acetylaspartate (NAA) levels. Metabolic studies were performed and were unremarkable in all individuals. Transferrin glycoform analysis was performed in the blood of three out of the four affected individuals and was equally unremarkable (<xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="mmc1" ref-type="supplementary-material">supplemental subjects and methods</xref>).</p>
      <p id="p0035">Given that all four children harbor predicted loss-of-function variants of <italic>PGM2L1</italic>, we anticipated that such variants would reduce the level of glucose-1,6-bisphosphate and other sugar-bisphosphates that are normally synthesized by PGM2L1. Therefore, it was of interest to investigate these and other metabolites in PGM2L1-deficient versus control fibroblasts. Accordingly, a skin biopsy was obtained for functional studies as part of the clinical workup in three out of the four children, and consent for research usage was obtained. Residual deidentified biological material was used for fibroblast-based functional assays (Mayo Clinic IRB 16-004682-19). Deidentified data on participating individuals were collected under the&#xA0;oversight of the respective institutional review boards or equivalent ethical committees. Inspection of the chromatograms derived from the liquid chromatography/mass spectrometry (LCMS) analysis of the fibroblasts&#x2019; extracts showed a peak corresponding to an ion with an <italic>m/z</italic> value of 338.9890, matching mono-deprotonated glucose-1,6-bisphosphate, which was strongly reduced in extracts of fibroblasts deficient in PGM2L1. Nonetheless, an accurate quantification of glucose-1,6-bisphosphate&#xA0;was difficult to achieve via its <italic>m/z</italic> value (338.9890) because of a partial overlap of the elution profiles of glucose-1,6-bisphosphate and fructose-1,6-bisphosphate, which have the same elemental composition. Fortunately, we noticed that fragmentation of glucose-1,6-bisphosphate during electrospray ionization gave rise to an ion with an <italic>m/z</italic> value of 241.0121, which matched a fragment produced by the elimination of H<sub>3</sub>PO<sub>4</sub> and was at least 10-fold more abundant in the case of glucose-1,6-bisphosphate than of fructose-1,6-bisphosphate. On the basis of the analysis of this fragment (<italic>m/z</italic> value 241.0121), we could conclude that PGM2L1 deficiency led to an approximate 90% decrease in the concentration of glucose-1,6-bisphosphate but not to its complete absence (<xref rid="fig2" ref-type="fig">Figure&#xA0;2</xref>).<fig id="fig2"><label>Figure&#xA0;2</label><caption><p>Quantification of glucose-1,6-bisphosphate in cell extracts via LCMS</p><p>A fragment (<italic>m/z</italic>&#xA0;= 241.0121) formed through elimination of H<sub>3</sub>PO<sub>4</sub> in the LCMS analysis of the samples is 10-fold more abundant in the&#xA0;case of glucose-1,6-bisphosphate than fructose-1,6-bisphosphate. This allows the specific identification of low amounts of glucose-1,6-bisphosphate in cell extracts. The arrow indicates the glucose-1,6-bisphosphate (G-1,6-bisP) peak (red chromatogram; <italic>m/z</italic> = 338.9890) or the fragment that is formed through the elimination of H<sub>3</sub>PO<sub>4</sub> (black chromatogram; <italic>m/z</italic> = 241.0121) in control (CT) and in the affected individual&#x2019;s fibroblasts (PT1). The second peak shown corresponds to the same ions from fructose-1,6-bisphosphate. The peaks shown correspond to extracted-ion chromatograms of the [M-H]<sup>&#x2212;</sup> forms of each metabolite.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0040">Glucose-1,6-bisphosphate was consistently found to be reduced by about 10-fold in PGM2L1-deficient fibroblasts, regardless of whether the <italic>m/z</italic> values of ions 241.0121 (<xref rid="fig3" ref-type="fig">Figure&#xA0;3</xref>A) or 338.9890 (<xref rid="fig3" ref-type="fig">Figure&#xA0;3</xref>B) were used for the quantification, while fructose-1,6-bisphosphate (which is not formed by PGM2L1, but by phosphofructokinase) was unchanged. We similarly found that the concentrations of N-acetyl-glucosamine-1,6-bisphosphate and ribose-1,5-bisphosphate, two other products previously shown to be formed by PGM2L1 <italic>in&#xA0;vitro</italic>,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> were also markedly reduced in the PGM2L1-deficient fibroblasts, yet they were still significantly present (<xref rid="fig3" ref-type="fig">Figures 3</xref>C and 3D).<fig id="fig3"><label>Figure&#xA0;3</label><caption><p>Glucose-1,6-bisphosphate, N-acetyl-glucosamine-1,6-bisphosphate, and ribose-1,5-bisphosphate, but not NDP-sugars, are reduced in fibroblasts from PGM2L1-deficient individuals</p><p>Changes in glucose-1,6-bisphosphate (G-1,6-P<sub>2</sub>) and fructose-1,6-bisphosphate (F-1,6-P<sub>2</sub>) in control fibroblasts (n = 6) versus fibroblasts from PGM2L1-deficient individuals (n = 3: PT1, PT2, and PT3) are shown by integrating either both peaks (G-1,6-P<sub>2</sub> + F-1,6-P<sub>2</sub>) together or separately (G-1,6-P<sub>2</sub> or F-1,6-P<sub>2</sub>), indicating that only G-1,6-P<sub>2</sub> (and not F-1,6-P<sub>2</sub>) is reduced in PGM2L1-deficient fibroblasts (A and B). Other bisphosphates that decreased in fibroblasts from affected individuals are N-acetyl-hexosamine-1,6-bisphosphate (C) and ribose-1,5-bisphosphate (D). The peaks corresponding to the sum of UDP-glucose/UDP-galactose (E), or UDP-N-acetyl-glucosamine/UDP-N-acetyl-galactosamine (F), and to UDP-glucuronate (G), CMP-sialic acid (H), GDP-mannose/GDP-glucose (I), GDP-fucose (J), and ATP (K) or ADP (L) remain unchanged. Note that the peak corresponding to CDP-ribitol was also unchanged but could not be shown.</p><p>Bars represent metabolites detected by LCMS analysis corresponding to extracted-ion chromatograms of the [M-H]<sup>&#x2212;</sup> forms. Metabolites are quantified by integrating the areas under the curve corresponding to the shown metabolite and normalizing them to total ion current (TIC). Data shown are means and error bars are &#xB1; SD and correspond to fibroblasts from six different controls (n = 1 for each control) and three PGM2L1-deficient individuals (n = 2 for each affected individual).</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0045">Hexose-/pentose-bisphosphates are activators of phosphomutases, which are required for the synthesis of NDP-sugars.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Thus, a major question was whether the decrease in hexose- and pentose-bisphosphates might lower the level of NDP-sugars in these cells and thereby compromise protein glycosylation. However, no significant change was observed in the level of UDP-hexose (sum of UDP-glucose and UDP-galactose), UDP-glucuronate, UDP-GlcNAc/GalNAc, cytidine monophosphate (CMP)-sialic acid, GDP-mannose/GDP-glucose, GDP-fucose (<xref rid="fig3" ref-type="fig">Figures 3</xref>E&#x2013;3J), and cytidine diphosphate (CDP)-ribitol (see note in the legend of <xref rid="fig3" ref-type="fig">Figure&#xA0;3</xref>), indicating that the level of none of the precursors required for glycosylation reactions was affected. We also found that there was no change in the concentration of ATP and of ADP, two major nucleotides involved as substrate or product for a multitude of enzymes (<xref rid="fig3" ref-type="fig">Figures 3</xref>K and 3L). Experiments that were designed to rescue the PGM2L1 defect in fibroblasts from three PGM2L1-deficient individuals as well as a control individual showed that the level of the various hexose-bisphosphates were increased by 10- to 20-fold by complementation with PGM2L1 (<xref rid="mmc1" ref-type="supplementary-material">Figures S1</xref>A and S1B), reaching levels above the ones observed in control cells. In contrast, UDP-hexose, UDP-glucuronate, UDP-GlcNAc/GalNAc, CMP-sialic acid, ADP, and ATP were not changed (<xref rid="mmc1" ref-type="supplementary-material">Figures S1</xref>C&#x2013;S1H). Accordingly, LCMS analysis of extracts from HEK293T cells overexpressing either a glucose-1,6-bisphosphate degrading enzyme (PMM1) or two glucose-1,6-bisphosphate forming ones (PGM2 or PGM2L1) showed a strong decrease or increase in intracellular glucose-1,6-bisphosphate (<xref rid="mmc1" ref-type="supplementary-material">Figures S2</xref>A and S2B), N-acetyl-hexosamines-1,6-bisphosphate (<xref rid="mmc1" ref-type="supplementary-material">Figure&#xA0;S2</xref>C), and ribose-1,5-bisphosphate (<xref rid="mmc1" ref-type="supplementary-material">Figure&#xA0;S2</xref>D) without impacting the levels of NDP-sugars, CMP-sialic acid, ADP, or ATP (<xref rid="mmc1" ref-type="supplementary-material">Figures S2</xref>E&#x2013;S2J). Taken together, these data indicated that the loss of PGM2L1 activity in fibroblasts from PGM2L1-deficient individuals caused a significant yet incomplete loss of the hexose-/pentose-bisphosphates, activators of phosphomutases, but that this did not affect the level of the NDP-sugars, suggesting that protein glycosylation was most likely not affected.</p>
      <p id="p0050">In agreement, analysis by immunoblotting of the migration pattern of the heavily glycosylated protein LAMP2, whose glycans contribute to about 40% of its mass,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> shows that LAMP2 present in the extracts prepared from PGM2L1-deficient fibroblasts has the same normal migration pattern as the protein from control cells (<xref rid="fig4" ref-type="fig">Figure&#xA0;4</xref>A), which also argues against a glycosylation defect in the PGM2L1-deficient cells. We and others have shown in previous work that when glycosylation was impaired in cells, the migration pattern of LAMP2 was altered.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><fig id="fig4"><label>Figure&#xA0;4</label><caption><p>PGM2L1 deficiency in fibroblasts or PMM1 overexpression in HEK293T cells does not affect LAMP2 glycosylation because they lower, but do not abolish, glucose-1,6-bisphosphate in cells</p><p>PGM2L1 deficiency does not affect LAMP2 glycosylation in whole-cell extracts from fibroblasts as shown in immunoblots (A) while reducing, but not abolishing, glucose-1,6-bisphosphate. Glucose-1,6-bisphosphate was measured in neutralized HClO<sub>4</sub> extracts via a sensitive assay based on the stimulation of&#xA0;rabbit muscle phosphoglucomutase by glucose-1,6-bisphosphate (B). Equally, overexpression in HEK293T cells of PMM1, the IMP-dependent glucose-1,6-bisphosphate phosphatase, reduced, but did not abolish, glucose-1,6-bisphosphate (C) and did not result in reduced LAMP2 glycosylation, while G6PC3 deficiency markedly affected LAMP2 glycosylation in the neutrophils of these individuals (D).<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> PGM2 is not dedicated to form glucose-1,6-bisphosphate as PGM2L1 is, but it also displays significant glucose-1,6-bisphosphate synthase activity (C).</p><p>Measurements in (B) were made in double for fibroblasts from six control individuals (open symbols) and in triple for fibroblasts from three PGM2L1-deficient individuals (closed symbols). Data shown are means and error bars are &#xB1; SD. The medians between the two unmatched groups are compared via a&#xA0;nonparametric Mann-Whitney test and an exact p value was computed (<sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup>p &lt; 0.0001). In (C), data shown are means, error bars are &#xB1; SEM (n = 3), and p values (<sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup>p&#xA0;&#x2264; 0.0001) were determined with an unpaired t test.</p></caption><graphic xlink:href="gr4"/></fig></p>
      <p id="p0055">Because the changes in glucose-1,6-bisphosphate seen in LCMS (<xref rid="fig2" ref-type="fig">Figures 2</xref> and <xref rid="fig3" ref-type="fig">3</xref>) did not provide an absolute quantification, we also quantified glucose-1,6-bisphosphate in fibroblast extracts by using an enzymatic assay, which is based on the observation that phosphoglucomutase (PGM1) is activated by glucose-1,6-bisphosphate with a Ka (the concentration of enzyme activator at which half-maximal stimulation of the enzymatic activity is reached) below 1&#xA0;&#x3BC;M.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Thus, to determine the absolute concentration of glucose-1,6-bisphosphate in the PGM2L1-deficient cells, we used a spectrophotometric assay that is based on the stimulation of rabbit&#xA0;muscle phosphoglucomutase by glucose-1,6-bisphosphate.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> The use of appropriate dilutions of the extracts indicated that the intracellular concentration of glucose-1,6-bisphosphate amounted to 80&#xA0;&#x3BC;M in control fibroblasts and 13&#xA0;&#x3BC;M in PGM2L1-deficient ones (<xref rid="fig4" ref-type="fig">Figure&#xA0;4</xref>B). Consequently, even in PGM2L1-deficient cells, the concentration of glucose-1,6-bisphosphate was more than one order of magnitude above the Ka of PGM1 for glucose-1,6-bisphosphate, explaining that PGM2L1 deficiency does not affect the formation of UDP-glucose (<xref rid="fig3" ref-type="fig">Figure&#xA0;3</xref>E). A similar conclusion also applies to other phosphomutases because NDP-sugars dependent on the catalytic activity of PMM2 (GDP-mannose; <xref rid="fig3" ref-type="fig">Figure&#xA0;3</xref>I) and PGM3 (UDP-N-acetyl-hexosamine; <xref rid="fig3" ref-type="fig">Figure&#xA0;3</xref>F) were also not decreased.</p>
      <p id="p0060">Because PMM1 is the enzyme that serves to degrade glucose-1,6-bisphosphate<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> and PGM2 is a multifunctional enzyme that also catalyzes the synthesis of glucose-1,6-bisphosphate&#xA0;and other hexose-bisphosphates,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> although less well than PGM2L1, we tested the impact of overexpressing these enzymes in HEK293T cells on their level of glucose-1,6-bisphosphate. As expected, overexpression of PMM1 caused a marked decrease in the concentration of glucose-1,6-bisphosphate from 137&#xA0;&#x3BC;M to 25&#xA0;&#x3BC;M and confirmed that PGM2 is indeed able to form glucose-1,6-bisphosphate (<xref rid="fig4" ref-type="fig">Figure&#xA0;4</xref>C). PGM2 overexpression in HEK293T cells increased the concentration of this bisphosphate ester by about 2-fold, while that of PGM2L1, the enzyme dedicated to make sugar bisphosphates, including glucose-1,6-bisphosphate, increased it by about 20-fold (<xref rid="fig4" ref-type="fig">Figure&#xA0;4</xref>C). These findings are consistent with data published in the literature. As initially reported for PGM2 purified from human erythrocytes<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and confirmed with the recombinant enzyme,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> PGM2 also displays some glucose-1,6-bisphosphate synthase activity, despite its main phosphopentomutase activity. Furthermore the glucose-1,6-bisphosphate synthase activity of PGM2 is more powerfully inhibited by glucose-1,6-bisphosphate than that of PGM2L1,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> indicating that PGM2L1 is more suitable to form the elevated concentrations of glucose-1,6-bisphosphate (about 100&#xA0;nmol/g) that are found in mouse brain.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></p>
      <p id="p0065">Again, we noted that reduction of the glucose-1,6-bisphosphate pool due to PMM1 overexpression did not appear to impact glycosylation of LAMP2. By&#xA0;contrast, LAMP2 glycosylation was markedly affected in neutrophils from individuals with G6PC3 deficiency, owing to a block in glucose metabolism due to accumulation of the hexokinase inhibitor 1,5-anhydroglucitol-6-phosphate (<xref rid="fig4" ref-type="fig">Figure&#xA0;4</xref>D).<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> In this context, it is remarkable that the clinical features of our PGM2L1-deficient children are very similar to those observed in older individuals with MAN1B1-CDG (MIM: <ext-link ext-link-type="omim" xlink:href="614202" id="interref40">614202</ext-link>), a Golgi-related congenital disorder of glycosylation,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> but all four PGM2L1-deficient children had normal transferrin glycosylation in blood unlike MAN1B1-CDG-affected individuals.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref></p>
      <p id="p0070">Taken together, these findings suggest that PGM2L1 deficiency is not a glycosylation defect due to the defective production of NDP-sugars. Yet, while our analyses in fibroblasts and the normal transferrin glycosylation in PGM2L1-deficient individuals do not reveal changes in glycosylation, one could argue that PGM2L1 deficiency might lead to a specific glycosylation defect in the brain where PGM2 expression is low. However, even if this was true, it does not explain the need to have such elevated concentrations of hexose-/pentose-bisphosphates (and particularly glucose-1,6-bisphosphate)<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> in the brain together with the high expression of PGM2L1, an enzyme that is dedicated to their synthesis.</p>
      <p id="p0075">Although we have not explored directly the mechanism by which lack of PGM2L1 leads to the neurodevelopmental delay seen in these children, it is conceivable that glucose-1,6-bisphosphate and other sugar-bisphosphates made by PGM2L1 may have a regulatory role in sugar metabolism in the brain. Indeed, besides their actions as activators of phosphomutases, glucose-1,6-bisphosphate and ribose-1,5-bisphosphate have, in the range of concentrations observed in the brain, potential regulatory effects on several enzymes of sugar metabolism. <italic>In&#xA0;vitro</italic>, glucose-1,6-bisphosphate has also been described to be an inhibitor of hexokinase 1 and 2 (only at concentrations that are much higher than those needed to saturate phosphomutases)<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> and of phosphogluconate dehydrogenase.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Additionally, both glucose-1,6-bisphosphate<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> and ribose-1,5-bisphosphate<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> are stimulators of phosphofructokinase, although not as potent as fructose-2,6-bisphosphate, but more studies are needed to understand the physiological relevance of these effects or to discover the real target of glucose-1,6-bisphosphate&#x2019;s action.</p>
      <p id="p0080">Interestingly, degradation of glucose-1,6-bisphosphate is regulated by inosine monophosphate (IMP),<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> suggesting that it may have some role in the control of energy metabolism. The concentration of IMP increases in energy shortage as a result of enhanced deamination of AMP by AMP-deaminase. Glucose-1,6-bisphosphate is indeed degraded by PMM1,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> a protein homologous to PMM2, which in the presence of micromolar concentrations of IMP, efficiently dephosphorylates glucose-1,6-bisphosphate. The effect of IMP is not only impressive by its magnitude, the low Ka for IMP (&#x2248;1.5&#x2013;3&#xA0;&#x3BC;M), and the specificity for this nucleotide but also by the fact that mechanistically it involves conserved residues that are specific for PMM1 and not found in PMM2.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> The occurrence of this regulation <italic>in&#xA0;vivo</italic> is supported by the observation that the decrease in glucose-1,6-bisphosphate that occurs during anoxia in mouse brain<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> does not occur in PMM1-deficient mice.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> These findings, and the fact that the presence of this IMP-dependent phosphatase in the brain parallels that of the glucose-1,6-bisphosphate synthesizing enzyme,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> plead for a regulatory role of glucose-1,6-bisphosphate in response to energy shortage.</p>
      <p id="p0085">Would such a role be compatible with the phenotype that is observed in PGM2L1 deficiency? It may be interesting in this respect to remember that the phenotype of cerebral creatine deficiency syndrome 1 (CCDS1 [MIM: 30052]), an X-linked disease due to creatine transporter (SLC6A8) deficiency, shares several features with PGM2L1 deficiency, including intellectual disability, speech delay, and hypotonia, with only occasionally reported microcephaly.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> Creatine phosphate serves as an energy reservoir and for the intracellular transport of high-energy phosphates.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> The similarity of the clinical findings in these two metabolic diseases supports a potential role of glucose-1,6-bisphosphate in energy metabolism.</p>
      <p id="p0090">In summary, we report a neurodevelopmental disorder related to a deficiency in PGM2L1, a glucose-1,6-bisphosphate synthesizing enzyme that associates a neurological syndrome with dysmorphism. Studies on fibroblasts from affected and control individuals and cell lines overexpressing recombinant proteins clearly indicate that PGM2L1 deficiency causes a decrease, but not a disappearance, of the sugar bisphosphates needed for the formation of NDP-sugars and that there is no evidence that this leads to a glycosylation defect. This indicates that there must be an important role of glucose-1,6-bisphosphate and/or other hexose-/pentose-bisphosphates in the brain that is still unknown.</p>
    </sec>
    <sec sec-type="COI-statement" id="sec2">
      <title>Declaration of interests</title>
      <p id="p0095">The authors declare no competing interests</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>P&#xE9;anne</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>de Lonlay</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Foulquier</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Kornak</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Lefeber</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Morava</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>P&#xE9;rez</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Seta</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Thiel</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Van Schaftingen</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Congenital disorders of glycosylation (CDG): Quo vadis?</article-title>
          <source>Eur. J. Med. Genet.</source>
          <volume>61</volume>
          <year>2018</year>
          <fpage>643</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="pmid">29079546</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Beamer</surname>
              <given-names>L.J.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in hereditary phosphoglucomutase 1 deficiency map to key regions of enzyme structure and function</article-title>
          <source>J.&#xA0;Inherit. Metab. Dis.</source>
          <volume>38</volume>
          <year>2015</year>
          <fpage>243</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="pmid">25168163</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Mio</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yamada-Okabe</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Arisawa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yamada-Okabe</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Functional cloning and mutational analysis of the human cDNA for phosphoacetylglucosamine mutase: identification of the amino acid residues essential for the catalysis</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1492</volume>
          <year>2000</year>
          <fpage>369</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="pmid">11004509</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Matthijs</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Schollen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Pardon</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Veiga-Da-Cunha</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jaeken</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cassiman</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Van Schaftingen</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome)</article-title>
          <source>Nat. Genet.</source>
          <volume>16</volume>
          <year>1997</year>
          <fpage>88</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">9140401</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Najjar</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Pullman</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>The occurrence of a group transfer involving enzyme (phosphoglucomutase) and substrate</article-title>
          <source>Science</source>
          <volume>119</volume>
          <year>1954</year>
          <fpage>631</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">13156640</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Ray</surname>
              <given-names>W.J.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Roscelli</surname>
              <given-names>G.A.</given-names>
            </name>
          </person-group>
          <article-title>A Kinetic Study of the Phosphoglucomutase Pathway</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>239</volume>
          <year>1964</year>
          <fpage>1228</fpage>
          <lpage>1236</lpage>
          <pub-id pub-id-type="pmid">14165931</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Pirard</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Achouri</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Collet</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Schollen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Matthijs</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Van Schaftingen</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes</article-title>
          <source>Biochem. J.</source>
          <volume>339</volume>
          <year>1999</year>
          <fpage>201</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="pmid">10085245</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Stiers</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Muenks</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Beamer</surname>
              <given-names>L.J.</given-names>
            </name>
          </person-group>
          <article-title>Biology, Mechanism, and Structure of Enzymes in the &#x3B1;-d-Phosphohexomutase Superfamily</article-title>
          <source>Adv. Protein Chem. Struct. Biol.</source>
          <volume>109</volume>
          <year>2017</year>
          <fpage>265</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="pmid">28683921</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Ray</surname>
              <given-names>W.J.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Burgner</surname>
              <given-names>J.W.</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Post</surname>
              <given-names>C.B.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of vanadate-based transition-state-analogue complexes of phosphoglucomutase by spectral and NMR techniques</article-title>
          <source>Biochemistry</source>
          <volume>29</volume>
          <year>1990</year>
          <fpage>2770</fpage>
          <lpage>2778</lpage>
          <pub-id pub-id-type="pmid">2140697</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Rose</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Warms</surname>
              <given-names>J.V.</given-names>
            </name>
          </person-group>
          <article-title>PH dependence of the alpha-glucose 1,6-diphosphate inhibition of hexokinase II</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <volume>171</volume>
          <year>1975</year>
          <fpage>678</fpage>
          <lpage>681</lpage>
          <pub-id pub-id-type="pmid">968</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Maliekal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sokolova</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Vertommen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Veiga-da-Cunha</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Van Schaftingen</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Molecular identification of mammalian phosphopentomutase and glucose-1,6-bisphosphate synthase, two members of the alpha-D-phosphohexomutase family</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>282</volume>
          <year>2007</year>
          <fpage>31844</fpage>
          <lpage>31851</lpage>
          <pub-id pub-id-type="pmid">17804405</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Veiga-da-Cunha</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vleugels</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Maliekal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Matthijs</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Van Schaftingen</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-bisphosphatase</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>33988</fpage>
          <lpage>33993</lpage>
          <pub-id pub-id-type="pmid">18927083</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Passonneau</surname>
              <given-names>J.V.</given-names>
            </name>
            <name>
              <surname>Lowry</surname>
              <given-names>O.H.</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>Glucose 1,6-diphosphate formation by phosphoglucomutase in mammalian tissues</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>244</volume>
          <year>1969</year>
          <fpage>902</fpage>
          <lpage>909</lpage>
          <pub-id pub-id-type="pmid">5814030</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Sobreira</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Schiettecatte</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Valle</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hamosh</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title>
          <source>Hum. Mutat.</source>
          <volume>36</volume>
          <year>2015</year>
          <fpage>928</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="pmid">26220891</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Terasawa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tomabechi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ehara</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kukimoto-Niino</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wakiyama</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Podyma-Inoue</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Rajapakshe</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Watabe</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shirouzu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hara-Yokoyama</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Lysosome-associated membrane proteins-1 and -2 (LAMP-1 and LAMP-2) assemble via distinct modes</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>479</volume>
          <year>2016</year>
          <fpage>489</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="pmid">27663661</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Wortmann</surname>
              <given-names>S.B.</given-names>
            </name>
            <name>
              <surname>Van Hove</surname>
              <given-names>J.L.K.</given-names>
            </name>
            <name>
              <surname>Derks</surname>
              <given-names>T.G.J.</given-names>
            </name>
            <name>
              <surname>Chevalier</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Knight</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Koller</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Oussoren</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mayr</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>van Spronsen</surname>
              <given-names>F.J.</given-names>
            </name>
            <name>
              <surname>Lagler</surname>
              <given-names>F.B.</given-names>
            </name>
          </person-group>
          <article-title>Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor</article-title>
          <source>Blood</source>
          <volume>136</volume>
          <year>2020</year>
          <fpage>1033</fpage>
          <lpage>1043</lpage>
          <pub-id pub-id-type="pmid">32294159</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Ninfali</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Accorsi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Palma</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Fazi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Piatti</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Chiarantini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Fornaini</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Human erythrocyte phosphoglucomutase: comparison of the kinetic properties of PGM1 and PGM2 isoenzymes</article-title>
          <source>Biochimie</source>
          <volume>66</volume>
          <year>1984</year>
          <fpage>617</fpage>
          <lpage>623</lpage>
          <pub-id pub-id-type="pmid">6240990</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Accorsi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Piatti</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Piacentini</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Gini</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fazi</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Isoenzymes of phosphoglucomutase from human red blood cells: isolation and kinetic properties</article-title>
          <source>Prep. Biochem.</source>
          <volume>19</volume>
          <year>1989</year>
          <fpage>251</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="pmid">2533352</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Yip</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>Z.B.</given-names>
            </name>
            <name>
              <surname>Lowry</surname>
              <given-names>O.H.</given-names>
            </name>
          </person-group>
          <article-title>Distribution of glucose-1,6-bisphosphate and IMP-activated glucose bisphosphatase in brain and retina</article-title>
          <source>J.&#xA0;Neurochem.</source>
          <volume>44</volume>
          <year>1985</year>
          <fpage>1741</fpage>
          <lpage>1746</lpage>
          <pub-id pub-id-type="pmid">2985763</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreira</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Altassan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marques-Da-Silva</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Francisco</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Jaeken</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Morava</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Recognizable phenotypes in CDG</article-title>
          <source>J.&#xA0;Inherit. Metab. Dis.</source>
          <volume>41</volume>
          <year>2018</year>
          <fpage>541</fpage>
          <lpage>553</lpage>
          <pub-id pub-id-type="pmid">29654385</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Van Scherpenzeel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Timal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rymen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hoischen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wuhrer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hipgrave-Ederveen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Grunewald</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Peanne</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Saada</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Edvardson</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency</article-title>
          <source>Brain</source>
          <volume>137</volume>
          <year>2014</year>
          <fpage>1030</fpage>
          <lpage>1038</lpage>
          <pub-id pub-id-type="pmid">24566669</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal" id="sref22">
          <person-group person-group-type="author">
            <name>
              <surname>Climent</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Carreras</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Carreras</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Metabolism of glucose 1,6-P2. I. Enzymes involved in the synthesis of glucose 1,6-P2 in pig tissues</article-title>
          <source>Comp. Biochem. Physiol. B</source>
          <volume>81</volume>
          <year>1985</year>
          <fpage>737</fpage>
          <lpage>742</lpage>
          <pub-id pub-id-type="pmid">2992877</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Beitner</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nordenberg</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The participation of glucose-1,6-diphosphate in the regulation of hexokinase and phosphoglucomutase activities in brains of young and adult rats</article-title>
          <source>Int. J. Biochem.</source>
          <volume>14</volume>
          <year>1982</year>
          <fpage>195</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">6461568</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>Crane</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Sols</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>210</volume>
          <year>1954</year>
          <fpage>597</fpage>
          <lpage>606</lpage>
          <pub-id pub-id-type="pmid">13211596</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Sprengers</surname>
              <given-names>E.D.</given-names>
            </name>
            <name>
              <surname>Koenderman</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Staal</surname>
              <given-names>G.E.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial and cytosolic hexokinase from rat brain: one and the same enzyme?</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>755</volume>
          <year>1983</year>
          <fpage>112</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">6824726</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>Gerber</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Preissler</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Heinrich</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Rapoport</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Hexokinase of human erythrocytes. Purification, kinetic model and its application to the conditions in the cell</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>45</volume>
          <year>1974</year>
          <fpage>39</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">4421639</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Beitner</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Nordenberg</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of 6-phosphogluconate dehydrogenase (decarboxylating) by glucose 1,6-bisphosphate</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>583</volume>
          <year>1979</year>
          <fpage>266</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="pmid">375989</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Nordenberg</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Aviram</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Beery</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Stenzel</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Novogrodsky</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of 6-phosphogluconate dehydrogenase by glucose 1,6-diphosphate in human normal and malignant colon extracts</article-title>
          <source>Cancer Lett.</source>
          <volume>23</volume>
          <year>1984</year>
          <fpage>193</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">6234985</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>Andr&#xE9;s</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Carreras</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cuss&#xF3;</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Activation of muscle phosphofructokinase by alpha-glucose 1,6-bisphosphate and fructose 2,6-bisphosphate is differently affected by other allosteric effectors and by pH</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>157</volume>
          <year>1988</year>
          <fpage>664</fpage>
          <lpage>669</lpage>
          <pub-id pub-id-type="pmid">2974284</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>Ishikawa</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ogushi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Uyeda</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Activation of mammalian phosphofructokinases by ribose 1,5-bisphosphate</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>265</volume>
          <year>1990</year>
          <fpage>18875</fpage>
          <lpage>18878</lpage>
          <pub-id pub-id-type="pmid">2146265</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Guha</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>Z.B.</given-names>
            </name>
          </person-group>
          <article-title>Brain glucose bisphosphatase requires inosine monophosphate</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>257</volume>
          <year>1982</year>
          <fpage>6634</fpage>
          <lpage>6637</lpage>
          <pub-id pub-id-type="pmid">6282819</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Guha</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>Z.B.</given-names>
            </name>
          </person-group>
          <article-title>Role of inosine 5&#x2032;-phosphate in activating glucose-bisphosphatase</article-title>
          <source>Biochemistry</source>
          <volume>22</volume>
          <year>1983</year>
          <fpage>1356</fpage>
          <lpage>1361</lpage>
          <pub-id pub-id-type="pmid">6301545</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>Ji</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Dunaway-Mariano</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>K.N.</given-names>
            </name>
          </person-group>
          <article-title>Structural Basis of the Molecular Switch between Phosphatase and Mutase Functions of Human Phosphomannomutase 1 under Ischemic Conditions</article-title>
          <source>Biochemistry</source>
          <volume>57</volume>
          <year>2018</year>
          <fpage>3480</fpage>
          <lpage>3492</lpage>
          <pub-id pub-id-type="pmid">29695157</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>Yip</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Pusateri</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Lowry</surname>
              <given-names>O.H.</given-names>
            </name>
          </person-group>
          <article-title>Distribution of the glucose-1,6-bisphosphate system in brain and retina</article-title>
          <source>J.&#xA0;Neurochem.</source>
          <volume>50</volume>
          <year>1988</year>
          <fpage>594</fpage>
          <lpage>602</lpage>
          <pub-id pub-id-type="pmid">2826701</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>van de Kamp</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Betsalel</surname>
              <given-names>O.T.</given-names>
            </name>
            <name>
              <surname>Mercimek-Mahmutoglu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Abulhoul</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gr&#xFC;newald</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Anselm</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Azzouz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bratkovic</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>de Brouwer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hamel</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Phenotype and genotype in 101 males with X-linked creatine transporter deficiency</article-title>
          <source>J.&#xA0;Med. Genet.</source>
          <volume>50</volume>
          <year>2013</year>
          <fpage>463</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="pmid">23644449</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Saks</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kaambre</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Guzun</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Anmann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sikk</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Schlattner</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Wallimann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Aliev</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vendelin</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The creatine kinase phosphotransfer network: thermodynamic and kinetic considerations, the impact of the mitochondrial outer membrane and modelling approaches</article-title>
          <source>Subcell. Biochem.</source>
          <volume>46</volume>
          <year>2007</year>
          <fpage>27</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">18652071</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="app1">
      <title>Data and code availability</title>
      <p id="p0105">The WES datasets have not been deposited in a public database because of privacy and ethical limitations but can be made available on request.</p>
    </sec>
    <sec id="app4">
      <title>Web resources</title>
      <p id="p0120">
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <p id="p0125">GenBank, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/genbank/" id="intref0025">https://www.ncbi.nlm.nih.gov/genbank/</ext-link></p>
          </list-item>
          <list-item id="u0015">
            <p id="p0130">Online Mendelian Inheritance in Man (OMIM), <ext-link ext-link-type="uri" xlink:href="https://www.omim.org/" id="intref0030">https://www.omim.org/</ext-link></p>
          </list-item>
        </list>
      </p>
    </sec>
    <sec id="app3" sec-type="supplementary-material">
      <title>Supplemental information</title>
      <p id="p0115">
        <supplementary-material content-type="local-data" id="mmc1">
          <caption>
            <title>Document S1. Figures S1 and S2 and supplemental subjects and methods</title>
          </caption>
          <media xlink:href="mmc1.pdf"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="mmc2">
          <caption>
            <title>Document S2. Article plus supplemental information</title>
          </caption>
          <media xlink:href="mmc2.pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack id="ack0010">
      <title>Acknowledgments</title>
      <p id="p0100">The authors would like to thank the individuals and their families for their participation in this study. Funding for this work was provided by the FNRS (<funding-source id="gs1">Fonds National de la Recherche Scientifique</funding-source>) (J.0224.20 and T.0239.21 to M.V.-d.-C.; J.0139.18 to E.V.S.; ARC17/22-079 to&#xA0;G.T.B.; equipment grant C 61/5 &#x2013; EQP/PGY to G.T.B. and M.V.-d.-C.), by the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100007601</institution-id><institution>European Commission Horizon 2020</institution></institution-wrap></funding-source> research and innovation program under the ERA-NET cofund action no. 643578, and the <funding-source id="gs3">Fonds Maurange</funding-source> to E.V.S. Part of this work was funded by the grant titled Frontiers in Congenital Disorders of Glycosylation to E.M. (1U54NS115198-01) from <funding-source id="gs4">the National Institute of Neurological Diseases and Stroke</funding-source> (NINDS) and <funding-source id="gs5">the National Center for Advancing Translational Sciences</funding-source> (NCATS) and <funding-source id="gs6">the Rare Disorders Clinical Research Network</funding-source> (RDCRN) at the National Institutes of Health. M.V.-d.-C. is &#x201C;Chercheur qualifi&#xE9;,&#x201D; S.P. is &#x201C;Charg&#xE9; de Recherche,&#x201D; and G.T.B. is &#x201C;Ma&#xEE;tre de Recherche&#x201D; of the FNRS. T.B.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, <funding-source id="gs7">German Research Foundation</funding-source>) (418081722 and 433158657).</p>
    </ack>
    <fn-group>
      <fn id="app2" fn-type="supplementary-material">
        <p id="p0110">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajhg.2021.04.017" id="intref0020">https://doi.org/10.1016/j.ajhg.2021.04.017</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>